Topical Eflornithine for Pseudofolliculitis Barbae: RCT

• Status: Not yet recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the efficacy of topical eflornithine for pseudofolliculitis barbae from a quality of life standpoint and with objective physician-measured lesion counts. Our hypothesis is that the hair growth retardation that occurs with eflornithine will perhaps reduce the frequency over time that service members need to shave which could improve the formation of PFB lesions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Walter Reed National Military Medical Center
• Treatments: Eflornithine

Criteria

Inclusion Criteria:

• Active Duty Service Members with Pseudofolliculitis Barbae

Exclusion Criteria:

• Previous treatment with laser hair removal in the previous 12 months, Currently pregnant, seeking pregnancy, or breast feeding